Back HCV Treatment

EASL 2014: BMS Dual Combo Cures 90% of Genotype 1b Hepatitis C in 24 Weeks

A combination of 2 direct-acting antivirals developed by Bristol-Myers Squibb (BMS), daclatasvir and asunaprevir, cured 90% of previously untreated people with genotype 1b hepatitis C in 24 weeks, without the need for pegylated interferon or ribavirin, Michael Manns of Hannover Medical School reported at the 49thEASL International Liver Congress (EASL 2014) in London last week.


Read more: